Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics
Authors
Keywords
Heterogeneity, Imaging, Non-small cell lung cancer, Pharmacology
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-04-25
DOI
10.1007/s00280-019-03840-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data
- (2017) Justin Guinney et al. LANCET ONCOLOGY
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
- (2016) Aaron N Hata et al. NATURE MEDICINE
- Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression
- (2016) Fedor V. Moiseyenko et al. Oncology Research and Treatment
- Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology
- (2015) Andreas Heindl et al. LABORATORY INVESTIGATION
- The Project Data Sphere Initiative: Accelerating Cancer Research by Sharing Data
- (2015) A. K. Green et al. ONCOLOGIST
- Tumour heterogeneity and the evolution of polyclonal drug resistance
- (2014) Rebecca A. Burrell et al. Molecular Oncology
- First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
- (2013) J-Y Douillard et al. BRITISH JOURNAL OF CANCER
- Cancer heterogeneity: implications for targeted therapeutics
- (2013) R Fisher et al. BRITISH JOURNAL OF CANCER
- Project Data Sphere to Make Cancer Clinical Trial Data Publicly Available
- (2013) K. Hede JNCI-Journal of the National Cancer Institute
- Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial
- (2012) Rodryg Ramlau et al. JOURNAL OF CLINICAL ONCOLOGY
- Weeklynab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
- (2012) Mark A. Socinski et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial
- (2012) Giorgio V. Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2011) Ronald B. Natale et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling
- (2011) J. Chmielecki et al. Science Translational Medicine
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
- (2010) Roy S Herbst et al. LANCET ONCOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- (2008) Edward S Kim et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search